Clinical Trial Update: Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME) [Phase 3]

View source ↗

Summary

Phase 3 trial results update for dupilumab in prurigo nodularis (LIBERTY-PN PRIME) has been completed with results posted in December 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prurigo Nodularis

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Sanofi | Conditions: Neurodermatitis | Phase 3 | Status: COMPLETED | Results posted: 2022-12-12